Connect with us

Health

Corona vaccine: Moderna vaccine can give people three months Safety from Covid-19 – Research

American company Moderna’s vaccine can protect people from Covid-19 (Corona) disease for at least 3 months. The research has been revealed in the report published in the journal ‘The

Published

on

Covid-19 vaccine: Moderna vaccine can give people three months Safety from Covid-19 - Research

Corona vaccine: American company Moderna’s vaccine can protect people from Covid-19 disease for at least 3 months. The research has been revealed in the report published in the journal ‘The New England Journal of Medicine’.

Also Check: Corona vaccine: Corona vaccine to be made using 500 things including shark liver oil

Moderna’s covid-19 vaccine can provide protection for three months

According to the report, researchers from the US National Institute of Allergy and Infectious Diseases (NIAID) investigated the immune response to vaccines in 34 adults. All people were given 2 doses of the vaccine in the first stage human trial of mRNA-1273. The report said that the level of anti bodies in people was investigated for the second time after 90 days of the vaccine dose (119 days after the first dose).

Advertisement

Researchers reported that antibodies that made the virus inactive in the blood were still present after 3 months and indicated that the body had some degree of protection against Corona even after so many months. However, this does not mean that the vaccine will not protect against disease after 90 days.

Also Check: Coffee Good For Your Gut, Potential Protective Affect Against Gallstones

However, he said that there is a need to do research in this regard on a larger scale. Which can prove how long the immune response against Covid-19 can remain intact. Research has revealed that a certain type of T-cell develops from the vaccine. Which shows that long-term security can be achieved to some extent.

Advertisement

The researchers said that these immune cells were revealed 43 days after the first vaccine. “The data from the first phase of human testing of the vaccine showed that our vaccine became virus-neutralizing antibodies in people of all ages,” said Talla Jacques, the Chief Medical Officer of Moderna. He told that there is more hope from the data that it will be more effective in providing protection from Kovid-19.

Let us tell you that the Moderna company first started human trials of its vaccine in March and informed the preliminary results of the final phase in early November. It said that his vaccine is 95 percent effective in providing protection against Kovid-19. It was also told that none of the people on whom the vaccine was tested showed symptoms of the disease.

After the final results, the company has also submitted applications and data in the US and Europe for approval of the emergency use of the vaccine. Moderna’s vaccine uses mRNA technology like Pfizer and the German company BioNotech. For this, help was obtained from the genetic code of the virus.

Advertisement

Volunteer claims no side-effects from vaccine

In the final phase trial of the vaccine, 30,000 volunteers were included. Of them, 196 people were confirmed to have corona infection, 30 people were seriously ill while one died. But none of them had been vaccinated by Moderna, rather they were part of the placebo group.

Also Check: Human Sperm Swims in Entirely Different Way Than Earlier Thought

The company says that there were no side-effects of the vaccine. Common symptoms such as swelling, headache and fatigue were found only at the site of injection. Moderna said that the data is not fully revealed yet. The Food and Drug Administration will meet on December 17 to approve the use of Moderna’s vaccine in the US.

Advertisement

Over the last 4 years, Vishnu has consistently demonstrated his commitment to writing articles and news pieces. His dedication to the craft is apparent in his continuous contributions, reflecting a passion for delivering informative and engaging content.

Health

IIT-K and BFI collaborate to drive healthcare innovation in India

Published

on

By

IIT-K and BFI forge partnership to accelerate healthcare innovation in India

Kanpur, April 17 (IANS) – The Indian Institute of Technology Kanpur (IIT-K) has entered into a strategic partnership with Blockchain For Impact (BFI) to drive advancements in healthcare in India. Under the BFI-Biome Virtual Network Programme, this collaboration aims to nurture innovations in the healthcare sector.

As part of the partnership, BFI will support IIT Kanpur in promoting entrepreneurial initiatives through the Startup Incubation & Innovation Centre (SIIC). A Memorandum of Understanding (MoU) was signed at IIT Kanpur by Prof. Kantesh Balani, Dean of Resources and Alumni (DoRA), IIT Kanpur; and Dr. Gaurav Singh, CEO BFI.

BFI has committed to allocating over $150,000 across three years to develop programmes tailored to healthcare-focused startups at IIT Kanpur’s SIIC. This collaboration harnesses IIT Kanpur’s expertise in fostering entrepreneurship and BFI’s dedication to advancing biomedical research.

Prof. Kantesh Balani, DoRA, IIT Kanpur, expressed his optimism about the partnership, stating, “This MoU will help us share knowledge, support startups effectively, and improve our capacity-building efforts.” Dr. Gaurav Singh, CEO of BFI, highlighted the inspiring work of IIT Kanpur incubatees in healthcare innovation and the alignment of missions to accelerate impactful solutions in biomedical research.

This partnership signifies a significant step towards advancing healthcare innovation in India by leveraging expertise and resources. The collaboration between IITK and BFI holds promise for improving public health and ensuring equitable healthcare access for all.

Continue Reading

Health

Doctors are hopeful that gene therapy could be a breakthrough for haemophilia, a blood disorder

Published

on

By

Gene therapy holds promise for blood disorder haemophilia: Doctors

On World Haemophilia Day, doctors highlighted the potential of gene therapy in treating haemophilia, a hereditary blood disorder. Haemophilia is caused by missing or defective clotting factors and raises the risk of severe bleeding and joint damage. Genetic counselling and screening are crucial for affected individuals. India has a high number of haemophilia cases, but many go undiagnosed due to lack of screening capabilities.

Gene therapy offers a promising approach to treating haemophilia by delivering functional genes to correct the genetic defect responsible for deficient clotting factor production. Recent clinical trials show positive outcomes, including the use of lentiviral vectors at CMC Vellore. While current treatment involves factor VIII infusions, gene therapy may offer a cure for haemophilia, especially in low and middle-income countries.

According to Anoop P, Sr. Consultant – Haematology at Aster RV Hospital, “Gene therapy is a potentially curative treatment for haemophilia.” It allows for editing the faulty gene of a baby inside the uterus, known to be born with haemophilia due to a family history. Ongoing research on gene therapy shows promising results, indicating a potential paradigm shift in the management and cure of haemophilia.

Continue Reading

Health

The Connection Between Daytime Sleep and Increased Risk of Dementia

Published

on

By

How daytime sleep can raise dementia risk

New Delhi, April 17 (IANS) Compensating for lack of sleep during the daytime may not be as effective as previously thought, warned Dr. Sudhir Kumar, a neurologist based in Hyderabad. According to Dr. Sudhir, daytime sleep is not in sync with the body’s natural clock and can increase the risk of dementia and other psychiatric disorders.

Dr. Sudhir, from Indraprastha Apollo Hospitals, highlighted in a post on X.com that daytime sleep is lighter and does not fulfill the body’s sleep requirements. He explained, “This fact is supported by numerous studies of night shift workers, who are predisposed to stress, obesity, cognitive deficits, and an elevated risk of neurodegenerative diseases.”

The neurologist pointed out that the glymphatic system, responsible for clearing the brain of protein waste products, is most active during sleep. Therefore, when there is a lack of sleep, the glymphatic system may fail, increasing the risk of dementia. Dr. Sudhir stated, “Glymphatic failure is the common pathway of dementia, leading to the accumulation of abnormal proteins in the brain.”

Factors such as poor sleep quality, age, sedentary lifestyle, cardiovascular diseases, obesity, sleep apnoea, circadian misalignment, substance abuse, and depression can also suppress or result in the failure of the glymphatic system. Dr. Sudhir emphasized, “Good sleepers tend to live longer, weigh less, have a reduced incidence of psychiatric disorders, and maintain cognitive function for longer periods.”

In conclusion, Dr. Sudhir advised that consistently sleeping well at night can lead to better cognitive function and decrease the risk of dementia and psychiatric disorders. It is essential to prioritize quality sleep to maintain overall brain health and reduce the risk of neurodegenerative diseases.

–IANS
rvt/

Continue Reading

Trending

This will close in 5 seconds